Evaluation of the Cost Per Patient Achieving Treatment Targets with Oral Semaglutide: A Short-Term Cost-Effectiveness Analysis in the United States

INTRODUCTION: Oral semaglutide is the first orally administered glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes, and has been evaluated in the PIONEER clinical trial program. These trials assessed the proportions of patients achieving single and composite endpoints, enc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Ther
Main Authors: Hunt, Barnaby, Hansen, Brian B., Ericsson, Åsa, Kallenbach, Klaus, Ali, Sarah N., Dang-Tan, Tam, Malkin, Samuel J. P., Valentine, William J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6860465/
https://ncbi.nlm.nih.gov/pubmed/31650514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-01125-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados